Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Invested Capital (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Invested Capital data on record, last reported at $654.3 million in Q4 2025.

  • For Q4 2025, Invested Capital rose 107.49% year-over-year to $654.3 million; the TTM value through Dec 2025 reached $654.3 million, up 107.49%, while the annual FY2025 figure was $654.3 million, 107.49% up from the prior year.
  • Invested Capital reached $654.3 million in Q4 2025 per OCUL's latest filing, up from $258.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $654.3 million in Q4 2025 and bottomed at $3.1 million in Q2 2023.
  • Average Invested Capital over 5 years is $189.9 million, with a median of $113.1 million recorded in 2021.
  • Peak YoY movement for Invested Capital: plummeted 95.31% in 2023, then surged 12135.02% in 2024.
  • A 5-year view of Invested Capital shows it stood at $120.9 million in 2021, then plummeted by 39.72% to $72.9 million in 2022, then soared by 76.49% to $128.6 million in 2023, then skyrocketed by 145.15% to $315.3 million in 2024, then surged by 107.49% to $654.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $654.3 million in Q4 2025, $258.2 million in Q3 2025, and $305.9 million in Q2 2025.